Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Assets Average (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Assets Average for 13 consecutive years, with $102.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average fell 42.17% year-over-year to $102.3 million, compared with a TTM value of $102.3 million through Dec 2025, down 42.17%, and an annual FY2025 reading of $136.4 million, down 32.61% over the prior year.
  • Assets Average was $102.3 million for Q4 2025 at Karyopharm Therapeutics, up from $100.6 million in the prior quarter.
  • Across five years, Assets Average topped out at $342.0 million in Q1 2023 and bottomed at $100.6 million in Q3 2025.
  • Average Assets Average over 5 years is $235.3 million, with a median of $262.8 million recorded in 2021.
  • The sharpest move saw Assets Average rose 16.42% in 2023, then tumbled 50.15% in 2025.
  • Year by year, Assets Average stood at $279.7 million in 2021, then increased by 5.36% to $294.7 million in 2022, then fell by 13.4% to $255.2 million in 2023, then crashed by 30.66% to $176.9 million in 2024, then tumbled by 42.17% to $102.3 million in 2025.
  • Business Quant data shows Assets Average for KPTI at $102.3 million in Q4 2025, $100.6 million in Q3 2025, and $116.3 million in Q2 2025.